

6 January 2025

Our Ref: FOI 405

Dear

**Freedom of Information Act 2000
Information in Relation to Treatment of Prostate and Bladder Cancers.**

I am writing to confirm that the South Eastern Health & Social Care Trust (the Trust) has now completed its search for information relating to the above, which you requested on 27 November 2024. Please accept my apologies for the delay in responding to your request. Thank you for your understanding and forbearance.

A response to the questions you have raised has been provided by the Medicine, Unscheduled Care and Cancer Directorate and are attached in Appendix A.

If you are unhappy as to how this request has been handled, you have the right to seek a review within the Trust in the first instance. You should write to the Information Governance Department, Lough House, Ards Community Hospital (informationgovernance@setrust.hscni.net) within two months of the date of this response and your complaint will be considered and a response provided, within 20 working days of receipt.

If, after receiving a response, you remain unhappy, you can refer your complaint to the Information Commissioner at The Information Commissioner's Office –Northern Ireland, 3rd Floor, 14 Cromac Place, Belfast, BT7 2JB. It is important to note that if you refer any matter to the Information Commissioner, you will need to show evidence of having gone through the Trust's internal review procedure to try to resolve the matter with the Trust in the first instance.

If you have any queries about this letter, please do not hesitate to contact me. Please remember to quote the reference number above in any future communications.

Yours sincerely

Caroline Degans
Information Governance Officer

Q1. How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A1. Please see Table 1 below for the number of patients treated with the listed medicines between 1 July 2024 to the end of September 2024.

Table 1

Name of Medicine	Number of Patients Treated
1.1 Abiraterone (Zytiga or generic abiraterone)	7
1.2 Apalutamide (Erleada)	1
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	1
1.4 Darolutamide (Nubeqa)	2
1.5 Enzalutamide (Xtandi)	27

Q2. How many patients were treated with these products specifically for prostate cancer (ICD-10 code = C61) in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A2. Please see Table 2 below for the number of patients treated with the listed products between 1 July 2024 to the end of September 2024.

Table 2

Name of Medicine	Number of Patients Treated
2.1 Docetaxel for prostate cancer	7
2.2 Olaparib (Lynparza) for prostate cancer	Nil
2.3 Talazoparib (Talzenna) for prostate cancer	Nil

Q3. How many patients were treated with the following combinations in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A3. Please see Table 3 below for the number of patients treated with the listed combinations between 1 July 2024 to the end of September 2024.

Table 3

Name of Medicine	Number of Patients Treated
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT*	Nil
3.2 Olaparib (Lynparza) + Abiraterone	Nil

***Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuprorelin, triptorelin, degarelix, flutamide**

Q4. How many patients received the following products for non-metastatic hormone sensitive prostate cancer in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A4. Please see Table 4 below for the number of patients treated with the listed products between 1 July 2024 to the end of September 2024.

Table 4

Name of Medicine	Number of Patients Treated
4.1 Abiraterone	Nil
4.2 Enzalutamide	4

Q5. BLADDER CANCER

How many patients were treated for bladder cancer (ICD-10 code = C67*) with the following products in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A5. Please see Table 5 below for the number of patients treated with the listed products between 1 July 2024 to the end of September 2024.

Table 5

Name of Medicine	Number of Patients Treated
5.1 Atezolizumab (Tecentriq)	1
5.2 Avelumab (Bavencio)	5
5.3 Erdafitinib (Balversa)	Nil
5.4 Nivolumab (Opdivo)	Nil
5.5 Pembrolizumab (Keytruda)	Nil

Q6. Of the patients treated with nivolumab (Opdivo) for bladder cancer, how many were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A6. Please see Table 6 below for the number of patients treated in the following settings between 1 July 2024 to the end of September 2024.

Table 6

Name of Medicine	Number of Patients Treated
6.1 Nivolumab in combination with cisplatin and gemcitabine	Nil
6.2 Nivolumab monotherapy as adjuvant treatment	Nil
6.3 Nivolumab monotherapy in total	Nil

Q7. ATEZOLIZUMAB (TECENTRIQ)
How many patients were treated with atezolizumab (Tecentriq) for the following cancer types in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?

A7. Please see Table 7 below for the number of patients treated with atezolizumab (Tecentriq) for the following cancer types between 1 July 2024 to the end of September 2024.

Table 7

Name of Medicine	Number of Patients Treated
7.1 Lung Cancer	4
7.2 Breast Cancer	1
7.3 Hepatocellular Carcinoma	Nil

Q8. *How many of the patients treated with atezolizumab were treated in the following settings in the 3 months between 1st Jul 2024 to the end of Sep 2024, or latest 3-months for which data are available?*

A8. Please see Table 8 below for the number of patients treated with atezolizumab in the following settings between 1 July 2024 to the end of September 2024.

Table 8

Name of Medicine	Number of Patients Treated
8.1 Atezolizumab in combination with carboplatin and etoposide	Nil
8.2 Atezolizumab as adjuvant treatment	* See Below
8.3 Atezolizumab in combination with bevacizumab, carboplatin and paclitaxel	7

* The information requested is not held on a central information system. To obtain this information would require a manual review of records.

This would exceed the 'Appropriate Limit' as defined by the Freedom of Information Act 2000. The Trust therefore exempts the release of this information under Section 12(1).

12.-(1) Section 1(1) does not oblige a public authority to comply with a request for information if the authority estimates that the cost of complying with the request would exceed the appropriate limit.

In accordance with the Freedom of Information Act 2000 this statement acts as a Refusal Notice.